Search results
Results from the WOW.Com Content Network
Lisdexamfetamine, sold under the brand names Vyvanse and Elvanse among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. [16]
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
Vyvanse, also known as lisdexamfetamine, is classified by the DEA as a schedule II controlled substance, which is applied to drugs considered to have a high likelihood of being abused, and ...
Vyvanse (lisdexamfetamine) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder; Vyvanse is converted into Dexedrine in vivo; Viibryd – an antidepressant of the serotonin modulator and stimulators class; Vivactil (protriptyline) an antidepressant also used in the treatment of nerve pain
[236] [237] Vyvanse is marketed as once-a-day dosing as it provides a slow release of dextroamphetamine into the body. Vyvanse is available as capsules, and chewable tablets, and in seven strengths; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The conversion rate between lisdexamfetamine dimesylate (Vyvanse) to dextroamphetamine base is ...
U.S. psychiatrists are increasingly prescribing the popular weight-loss drug Wegovy to patients who gain weight from medicines used to treat mental disorders, such as schizophrenia or bipolar ...
When you re-gain weight, you might notice a hunger spike, since your metabolism and hormones have changed, says Dr. Apovian. This can lead you to crave foods that are high in sugar and fat, she says.
One study reported occurrences at regularly prescribed doses in approximately 0.1% of individuals within the first several weeks after starting amphetamine or methylphenidate therapy. [ 3 ] [ 4 ] [ 5 ] Methamphetamine psychosis, or long-term effects of stimulant use in the brain (at the molecular level), depend upon genetics and may persist for ...